FCM
FOLD

Fieldview Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Fieldview Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$650K Buy
+44,948
New +$644K 0.19% 184
2025
Q2 		– Sell
-28,309
Closed -$231K – 410
2025
Q1 		$231K Buy
+28,309
New +$262K 0.03% 371

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Fieldview Capital Management's FOLD Position: Q1 2026 in Review

Fieldview Capital Management opened a new position in Amicus Therapeutics (FOLD) in Q1 2026: 44,948 shares worth $650K. The stake represents 0.19% of the portfolio and ranks #184 among its holdings. This is a return to the name: Fieldview Capital Management previously reported a position in FOLD as recently as Q1 2025.

Fieldview Capital Management first reported a position in FOLD in Q1 2025 and has held it in 2 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Fieldview Capital Management held 44,948 shares of Amicus Therapeutics worth $650K as of Q1 2026.
  • Amicus Therapeutics was a new Fieldview Capital Management position in Q1 2026.
  • Amicus Therapeutics made up 0.19% of Fieldview Capital Management's portfolio in Q1 2026, its #184 holding.
  • Fieldview Capital Management first reported a position in Amicus Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Fieldview Capital Management's 13F filing for Q1 2026, filed 14 May 2026.